Welcome to the PlexusDx Education Hub, where we unpack GLP-1 and dual-agonist therapies, weight-management protocols, and the inherited biology behind every metabolic result
Percent of Survey Respondents Taking the Peptides Being Reviewed BPC-157: 18% TB-500: 16% Wolverine Stack (BPC-157 + TB-500): 18% Emideltide / DSIP: 16.7% Semax: 16% Epitalon: 14% KPV: 11.5% MOTS-c: 9% The peptides under review are often sold online with labels such as for research use only, meaning they are intended for laboratory research rather than human use
Your body regulates this tightly
While rodent studies showed thyroid C-cell tumors, clinical trials and post-marketing surveillance involving millions of patients have not established a causal link between semaglutide and medullary thyroid carcinoma in humans
The number of individuals with AUD in the general population receiving GLP-1-based medications is believed to greatly exceed the number who receive FDA-approved drug treatments for AUD
It binds to both GIP and GLP-1 receptors, which are G-protein-coupled receptors expressed in pancreatic beta cells, the gastrointestinal tract, adipose tissue, and the central nervous system
